Published Paper Details:

This thesis examines the effectiveness of curcumin against breast cancer and provides a compelling case for their value as cancer preventatives. Given that free radicals are primary factor behind the occurrence of cancer, phytochemical analysis of the chosen plant reveals the presence of flavonoids, which have strong antioxidant activity and are also known to be useful in treating malignant development. Curcumin and its analogous compounds, such as eugenol, eugenol orthodimer (also known as bis-eugenol or 3,3'-dimethoxy-5,5'-di-2-propenyl-1,1'-biphenyl-2,2'-diol), and isoeugenol, were examined to assess their impact on cell toxicity, ability to generate reactive oxygen species (ROS), and capacity to scavenge radicals. This article discusses the properties of curcumin, a yellow pigment present in the rhizome of the Curcuma longa plant. Curcumin has been extensively researched due to its various biological impacts, such as anti-inflammatory and antioxidant properties. The article delves into the underlying biological mechanisms and potential therapeutic benefits of utilizing curcumin as a treatment in cancer therapy. A natural substance with excellent therapeutic potential is curcumin. Numerous studies have demonstrated the wide range of biological activities of curcumin, one of which is its potent anti-inflammatory properties. A physiological and pathological process that is both complex and widespread is inflammation. A tablet is a unit solid dose form that includes the active drug, together with any necessary excipients. These dose forms are the most often utilized. The primary objective in the design and manufacturing of compressed tablets is to provide precise oral dosages of medication in the appropriate form, timing, and location, while safeguarding the chemical integrity of the drug at its targeted site of action. The efficacy of the administered drug can be notably influenced by factors such as the tablet's physical arrangement, production process, and overall chemical makeup. Nearly 40% of the novel chemical entities being discovered at this time are poorly water-soluble medicines, which are linked to sluggish drug absorption and eventual inadequate and variable bioavailability.